JCR Pharmaceuticals Co., Ltd. (TYO:4552)
Japan · Delayed Price · Currency is JPY 458.00
-17.00 (-3.58%)
Jun 19, 2026, 3:24 PM JST
JCR Pharmaceuticals Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 2,178 | -6,414 | 7,244 | 5,412 | 19,404 |
Depreciation & Amortization | 2,557 | 3,374 | 3,197 | 1,997 | 1,945 |
Loss (Gain) From Sale of Investments | -667 | - | - | - | - |
Loss (Gain) on Equity Investments | 184 | 467 | 1,090 | - | - |
Stock-Based Compensation | 84 | - | - | - | - |
Other Operating Activities | -716 | -2,276 | 1,982 | -8,280 | -2,520 |
Change in Accounts Receivable | -1,927 | 2,698 | -3,797 | 4,448 | -7,402 |
Change in Inventory | -1,853 | -822 | -2,437 | -3,877 | -1,082 |
Change in Accounts Payable | -66 | -2,003 | 1,854 | -2,892 | 1,305 |
Change in Other Net Operating Assets | 91 | -510 | 179 | -2,308 | -2,361 |
Operating Cash Flow | -135 | -5,486 | 9,312 | -5,500 | 9,289 |
Operating Cash Flow Growth | - | - | - | - | -10.17% |
Capital Expenditures | -11,427 | -9,888 | -1,526 | -7,654 | -11,333 |
Cash Acquisitions | - | - | -600 | -6,717 | - |
Divestitures | - | 145 | - | - | - |
Sale (Purchase) of Intangibles | -154 | - | -569 | -906 | - |
Investment in Securities | 1,670 | - | - | 259 | - |
Other Investing Activities | -2,593 | -131 | 5 | 16 | 8,083 |
Investing Cash Flow | -12,504 | -9,874 | -2,690 | -15,002 | -3,250 |
Short-Term Debt Issued | 15,087 | 14,805 | - | 3,000 | - |
Long-Term Debt Issued | 3,750 | 750 | 9,600 | 4,750 | 750 |
Total Debt Issued | 18,837 | 15,555 | 9,600 | 7,750 | 750 |
Short-Term Debt Repaid | - | - | -6,900 | - | - |
Long-Term Debt Repaid | -3,050 | -750 | -2,200 | -3,050 | -750 |
Total Debt Repaid | -3,050 | -750 | -9,100 | -3,050 | -750 |
Net Debt Issued (Repaid) | 15,787 | 14,805 | 500 | 4,700 | - |
Issuance of Common Stock | 8 | 21 | - | - | - |
Repurchase of Common Stock | - | -2,530 | 15 | 10 | 10 |
Common Dividends Paid | -2,441 | -2,505 | -2,500 | -2,739 | -2,169 |
Other Financing Activities | -49 | -55 | -46 | -23 | -20 |
Financing Cash Flow | 13,305 | 9,736 | -2,031 | 1,948 | -2,179 |
Foreign Exchange Rate Adjustments | 145 | 64 | 886 | 1,099 | 612 |
Miscellaneous Cash Flow Adjustments | - | 1 | - | 1 | - |
Net Cash Flow | 811 | -5,559 | 5,477 | -17,454 | 4,472 |
Free Cash Flow | -11,562 | -15,374 | 7,786 | -13,154 | -2,044 |
Free Cash Flow Margin | -28.68% | -46.49% | 18.16% | -38.30% | -4.00% |
Free Cash Flow Per Share | -94.76 | -124.16 | 62.09 | -105.37 | -16.46 |
Cash Interest Paid | 413 | 147 | 87 | 46 | 45 |
Cash Income Tax Paid | -763 | 2,284 | -1,982 | 8,279 | 2,517 |
Levered Free Cash Flow | -24,618 | -13,174 | 4,178 | -15,235 | 4,843 |
Unlevered Free Cash Flow | -24,370 | -13,077 | 4,232 | -15,207 | 4,871 |
Change in Working Capital | -3,755 | -637 | -4,201 | -4,629 | -9,540 |